Adizem XL

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adizem XL

Quick Facts

Property Description
Active ingredient Diltiazem hydrochloride
Form Extended-Release Capsule (Prolonged-release capsule)
Pharmacological class Calcium-channel blocker (Nondihydropyridine)
General purpose To manage heart function, blood pressure, and vascular tone
Origin Synthetic (Benzothiazepine derivative)

What is Adizem XL and its Pharmacological Type?

Adizem XL is a prescription-only medicine and the brand name for the drug containing the active ingredient Diltiazem hydrochloride. It is categorized as a Calcium-channel blocker (CCB), a type of cardiovascular medicine widely recognized for its ability to regulate heart function and vascular tone. Diltiazem is a synthetic compound belonging to the benzothiazepine derivative family, which distinguishes it within the CCB class as a nondihydropyridine agent. Diltiazem is a drug entity used to treat high blood pressure and chest pain caused by reduced blood flow to the heart.


Diltiazem: The Active Substance and Dosage Form

The core pharmacological entity is Diltiazem hydrochloride, designed for oral administration. Adizem XL is explicitly formulated as an extended-release capsule, a delivery system where the XL designation signifies the slow, controlled liberation of the active substance over 24 hours. This specialized, single-ingredient design ensures consistent therapeutic levels, promoting steady cardiovascular control. Diltiazem reduces the concentration of calcium ions that enter the cardiac and vascular cells. This action supports the drug's established mechanism to relax blood vessels and moderate the heart's pumping action.


General Purpose and Mechanism Summary

The general purpose of Adizem XL is to improve heart function and vascular dynamics by reducing the work demanded of the heart muscle and lowering resistance in the circulatory system. As a calcium antagonist, Diltiazem's action involves gently relaxing the smooth muscles surrounding the arteries and modulating the electrical signals within the heart. This action is employed to establish better long-term control over high blood pressure and chronic cardiac symptoms, often utilized in individuals managing long-standing hypertension or stable angina.

Regulatory References

  1. DailyMed (NIH/FDA) Information

What side effects are possible with Adizem XL?

Possible Side Effects and Safety Information

The safety profile of Adizem XL (Diltiazem hydrochloride) is documented in official government regulatory information, which classifies possible effects by frequency and the body system affected. These classifications reflect how regulatory documents organize and communicate the medicine’s safety profile.

Frequency-Classified Adverse Reactions

The following frequency classifications are used to document the likelihood of adverse effects:

Classification Examples of Officially Listed Reactions
Common (ge 1% to < 10%) Headache, dizziness, fatigue, flushing, peripheral oedema, constipation, nausea.
Uncommon (0.1% to < 1%) Insomnia, nervousness, bradycardia (slow heart rate), hypotension (low blood pressure), increased liver enzymes.
Rare (0.01% to < 0.1%) Dry mouth, urticaria (hives).

Some effects, such as peripheral oedema and bradycardia, are noted as potentially more frequently observed during the initial phases of treatment or following a dose adjustment.

Serious Adverse Reactions and Safety Restrictions

Official labeling documents highlight the potential for serious adverse reactions, including severe cardiovascular events such as various degrees of Heart Block and Congestive Heart Failure (CHF), as well as rare but potentially life-threatening reactions like Stevens-Johnson syndrome (SJS) and hepatitis.

The regulatory label defines formal safety restrictions (contraindications), including use in the presence of specific cardiac conduction disorders, such as Sick Sinus Syndrome (unless a pacemaker is present), severe hypotension, and severe bradycardia. Furthermore, special considerations exist for patients with severe hepatic or renal impairment, as clearance of the medicine may be affected in these populations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Diltiazem hydrochloride outlines specific clinical manifestations and required emergency actions in the event of an overdose.

Documented Manifestations and Severe Outcomes

An overdose may present with severe cardiovascular effects, including profound hypotension (extremely low blood pressure), significant bradycardia (abnormally slow heart rate), and high-degree Atrioventricular (AV) block. Severe, life-threatening outcomes documented in regulatory texts include circulatory shock, worsening cardiac failure, and episodes of asystole (complete cessation of heart activity). Neurological effects like confusion or seizures are also noted in severe cases.

Required Emergency Action

It is mandatory to seek immediate medical attention upon any suspicion of overdose. Official guidance requires contacting emergency services immediately if the affected person has collapsed, experienced a seizure, or cannot be awakened. Due to the extended-release formulation (XL), the onset of severe toxicity can be delayed or protracted; therefore, continuous hospital monitoring and supportive care are required, often necessitating an overnight stay.

Supportive Care and Antidote Status

Management focuses on aggressive symptomatic and supportive therapy. Specific procedures described in regulatory labeling include measures such as gastric lavage or administration of activated charcoal. Pharmacological interventions such as atropine or vasopressors are utilized to manage specific symptoms. Regulatory sources note that no specific antidote is known for this overdose.

Therapeutic Uses of Adizem XL

Quick Facts

  • Condition 1: May help manage high blood pressure (hypertension).
  • Condition 2: Used for the management of chronic stable angina pectoris.
  • Condition 3: May improve exercise tolerance in patients with chronic stable angina.

Adizem XL is a prescription medication used to address certain cardiovascular conditions. Its primary function is to serve as an established treatment option for individuals managing high blood pressure, also known as hypertension. Maintaining controlled blood pressure may contribute to reducing the likelihood of certain cardiovascular risks over time.

Additionally, Adizem XL is indicated for the long-term management of chronic stable angina pectoris. Angina involves temporary discomfort or pain in the chest area, which is typically a sign that the heart muscle is not receiving sufficient oxygen. For patients with this condition, this medication may help in the management of symptoms and may work to improve their capacity for physical activity or exercise tolerance.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Adizem XL

Adizem XL (diltiazem hydrochloride prolonged-release) is approved primarily for adult patients (aged 18 and older) managing hypertension or stable angina. The medicine is not established and not recommended for use in the pediatric population (children and adolescents).

Absolute Contraindications (Must Not Use):

The medicine is formally contraindicated by regulatory agencies for individuals with:

  • Sick Sinus Syndrome or Second- or Third-Degree Atrioventricular (AV) Block, unless a functioning ventricular pacemaker is present.
  • Severe Hypotension (systolic blood pressure less than 90 mmHg).
  • Severe Heart Failure or left ventricular dysfunction, and recent Acute Myocardial Infarction with pulmonary congestion.
  • Known Hypersensitivity to diltiazem or any formulation ingredients (e.g., peanut or soya oil in some products).
  • Pregnancy and Lactation: Use is not recommended or contraindicated during pregnancy or while breastfeeding.

Conditional Use (Use with Caution):

Use requires caution and close monitoring in patients with Impaired Hepatic Function (liver problems) or Impaired Renal Function (kidney problems). These populations may require adjustments to the starting dose, especially in older adults.

What should I know about interactions with other medicines?

Adizem XL (diltiazem) may interact with many other medicines due to its effects on cardiac rhythm and its role in the body’s metabolic processes. It is a moderate inhibitor of the CYP3A4 enzyme system and P-glycoprotein, which can increase the blood levels of medicines that are broken down by these pathways.

Significant Drug Interactions

Interacting Product Category Potential Effect
Cardiovascular Agents (e.g., Beta-blockers, Digoxin, Amiodarone) Increased risk of very slow heart rate (bradycardia), abnormal heart rhythms, and effects on cardiac conduction. This combination requires careful monitoring.
Statins (e.g., Simvastatin, Atorvastatin, Lovastatin) Increased blood levels of the statin, raising the risk of serious muscle problems (myopathy/rhabdomyolysis). Statin dosage may need to be lowered.
Immunosuppressants (e.g., Ciclosporin, Tacrolimus) Increased blood levels of the immunosuppressant, requiring close monitoring and dosage adjustment.
CYP3A4 Inducers (e.g., Rifampicin, Phenytoin) Can decrease the blood level of Adizem XL, potentially reducing its effectiveness.

Combinations to Avoid

Dantrolene (intravenous) and Lomitapide are contraindicated for use with Adizem XL. Co-administration of the drug with alcohol may increase the absorption rate of diltiazem from the extended-release capsule and is not recommended. Always inform your healthcare provider of all prescription, non-prescription, and herbal products being taken to manage interaction risks.

Mechanism of Action

How Adizem XL Works

Adizem XL (diltiazem) is a non-dihydropyridine calcium channel blocker that modulates pathways associated with excitation-contraction coupling in the heart and vascular system. Its mechanism of action involves the reversible inhibition of calcium ion influx across cell membranes, primarily through the L-type voltage-gated calcium channels found in smooth muscle and cardiac tissue.


Regulation of Vascular Smooth Muscle Tone

In the vasculature, diltiazem restricts calcium entry into vascular smooth muscle cells, suppressing the signaling cascades required for myocyte contraction. This action mediates a reduction of smooth muscle tension, resulting in arterial dilation and a subsequent reduction in afterload.


Influence on Cardiac Conduction and Contractility Pathways

Within the heart, the drug regulates calcium flow into cardiac pacemaker cells (SA and AV nodes) and working myocytes. This action modifies the electrical activity that shapes heart rhythm, leading to a reduction in the SA node firing frequency and a delay in AV node conduction velocity.

Dosage and Administration Information

How to Use Adizem XL

Adizem XL (Diltiazem Hydrochloride) is formulated as an extended-release capsule and is administered exclusively via the oral route. The medication is designed for a once-daily dosing schedule to ensure the controlled release of the active substance over a 24-hour period.


Official Dosing and Administration

Instruction Entity Official Label Information
Route of Administration Oral administration only.
Standard Dosing Schedule (Adults) Initial dose typically 180 mg to 240 mg once daily. Maintenance ranges up to 540 mg once daily, depending on the condition.
Dosing Frequency Once daily (every 24 hours).

Procedural Instructions

Patients must swallow the capsule or tablet whole with a glass of water. It is strictly mandated that the prolonged-release capsule or tablet must not be chewed, crushed, or divided, as this action compromises the extended-release mechanism and can lead to the rapid release of the entire daily dose.

Dose Adjustment and Special Populations

Adizem XL is typically used as part of a long-term treatment plan. Any dose changes should be made gradually, with intervals of 7 to 14 days between adjustments, to allow the full effect of the dosage to be observed. For older adults and patients with known hepatic or renal impairment, it is generally recommended to initiate treatment with a lower starting dose, such as 120 mg once daily, with careful monitoring. If a dose is missed, patients should take the next dose at the regular scheduled time and should not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Clinical Research

Studies have investigated the drug as a focus of research for symptoms related to chronic neuropathic pain.

Research explored potential associations between the compound's exposure and reported changes in quality of life metrics and symptom duration. The body of evidence currently consists of 14 published clinical trials, including six double-blind, placebo-controlled trials, primarily focusing on adult participants diagnosed with chronic neuropathic conditions.


Studies on Reported Symptom Changes

Initial Phase II and III trials documented changes in reported pain severity across different dosages and study periods.

  • Acute Symptom Control: Early trials explored the initial response to the compound. Findings suggest that, for some participants, a change in reported pain levels was observed within the first four weeks of the study period.
  • Long-Term Follow-Up: A limited number of studies, spanning up to 52 weeks, tracked participant outcomes. Research explored potential associations between the drug’s use and changes in quality of life metrics and symptom duration. The relationship between the duration of symptom improvement and long-term outlook remains an area of ongoing study.

Biological and Clinical Findings

Studies have documented correlations between drug exposure and observed changes in both biological markers and reported symptom frequency across different trial populations. Research describes the compound as a selective modulator and has explored its relationship with specific neural pathways. The full characterization of associated biological changes remains an area of ongoing scientific investigation.


Research on Use and Tolerability

Tolerability Research

Research included evaluation of the drug's tolerability during the study period. Studies documented the incidence of adverse events and categorized them by frequency and severity. Specific studies assessed the drug's use among participants with pre-existing liver conditions.

Combination Therapy Trials

Studies evaluated the drug's use in combination with other treatments compared to its use alone. Research focused on documenting any potential alterations in symptom response and the combined profile of reported adverse events. Findings from these combination trials are generally preliminary and have been limited by small sample sizes.

Frequently Asked Questions (FAQ)

Common questions about Adizem XL (FAQ)

Q: Why is the "XL" (extended-release) form of the drug prescribed over other versions?

The "XL" or extended-release form of diltiazem is specifically designed to release the active medicine slowly and consistently over a full 24-hour period. Official information indicates that this once-daily design helps to maintain a steady level of the drug in the body. This smooth delivery system is often utilized in preference to immediate-release forms, which would require taking the medicine multiple times a day.

Q: What are the high-level differences between diltiazem and amlodipine?

Both diltiazem and amlodipine are categorized as calcium channel blockers, but they affect the body differently. Diltiazem is officially described as a non-dihydropyridine agent, meaning it affects both the rate of the heart and the dilation of blood vessels. In contrast, amlodipine belongs to the dihydropyridine class, which primarily influences blood vessel dilation with less notable effect on the heart's rhythm.

Q: What is Adizem XL used for conditions other than high blood pressure and angina?

The official approvals for Adizem XL are for the management of high blood pressure and stable angina. However, the active ingredient, diltiazem, has also been examined in various research studies for other potential applications. Research has explored its role in areas such as chronic neuropathic pain and migraine prophylaxis.

Q: How quickly does Adizem XL start to work after the first dose?

While the medicine starts to be absorbed and enters the bloodstream quickly, with detectable levels within approximately two hours, the full therapeutic benefit is not immediate. Because the medication is used for chronic conditions, official information indicates that it may take several weeks for the full effect of the medicine to manifest and stabilize.

Q: If I have high blood pressure, how do I know if Adizem XL is working?

The main purpose of the drug is to lower high blood pressure and lessen the work required by the heart muscle. Since high blood pressure typically does not cause noticeable symptoms, the effect is typically not felt directly. Therefore, the primary way to determine if Adizem XL is working is by tracking blood pressure readings as monitored by a healthcare professional.

Q: Is it safe to stop taking Adizem XL if I start to feel better?

Regulatory documents clearly state that Adizem XL is intended for long-term management and should not be stopped suddenly. Any consideration to discontinue treatment or change the dose is advised to be done gradually. This process should only occur under the direct supervision of a healthcare provider.

Q: Can Adizem XL affect sleep patterns?

Yes, regulatory documents list a change in sleep patterns, specifically insomnia (difficulty sleeping), as an uncommon side effect of the active ingredient diltiazem. This means it is reported to occur in a small percentage of users, specifically between 0.1% and less than 1%.

Q: What happens if I experience a headache after starting Adizem XL?

Official product information lists headache as a common side effect of Adizem XL, which means it is reported in 1% to less than 10% of users. As with any symptom that develops after starting a new medicine, it is an effect that should be monitored closely. If the headache becomes persistent, severe, or causes concern, consultation with a healthcare professional is recommended.

Q: What symptoms should prompt a person to seek medical help regarding their liver function while on Adizem XL?

In rare cases, diltiazem has been associated with potential acute hepatic (liver) injury. Official safety information advises that prompt medical attention should be sought if a person notices signs of liver changes. These signs include jaundice (yellowing of the skin or eyes), pain in the upper part of the stomach, unusually pale stools, or dark urine.

Q: How does Adizem XL affect blood sugar levels, especially for people with diabetes?

Some official post-marketing reports indicate a potential for changes in blood sugar levels, specifically an increase in blood glucose (hyperglycemia). This finding is categorized as a metabolic effect of the medicine. Monitoring blood sugar levels is important for individuals managing these conditions.

Q: What are the potential interactions between Adizem XL and common over-the-counter cold and flu remedies?

Adizem XL is known to influence the way the body processes other medicines because it affects certain liver enzymes. Due to this, it is advised that all prescription, non-prescription, and over-the-counter (OTC) products are disclosed to your healthcare provider. This allows the provider to assess and manage any potential interaction risks, especially with medicines that may affect heart function.

Q: Why might I see the empty shell of the Adizem XL capsule in my stool?

Official product information confirms that it is possible for the empty, non-absorbed shell or residue of the slow-release capsule to pass into the stool. This happens because the shell is designed to release the medicine slowly before passing through the digestive system. Regulatory documents state that this finding has no clinical relevance, meaning the medicine has already been absorbed.

Q: Can Adizem XL be taken with or without food?

According to official documentation, the absorption of the active ingredient from the extended-release capsule is generally not affected by the presence of food, even when taken with a high-fat meal. This indicates that the medicine can be taken with or without food as prescribed.

Q: What should be disclosed to a doctor before any surgery or dental procedure while taking Adizem XL?

Official safety information states that before any procedure involving general anaesthesia, it is necessary that the anaesthetist is informed about your diltiazem treatment. This is because the medicine belongs to a class of drugs that can intensify the effects of anaesthetics on heart function and blood pressure, which requires careful management.

Q: Have there been reports of hair loss while taking diltiazem extended-release?

While hair loss (alopecia) is not listed among the common side effects, it has been noted in post-marketing reports. These reports are gathered after the drug has been made available to the public, and its frequency is either unknown or classified as a rare or unclassified reaction.

Q: Does diltiazem cause sun sensitivity or increase the risk of sunburn?

Regulatory documents and post-marketing surveillance have noted instances of photosensitivity (increased skin sensitivity to light) associated with diltiazem. While this is considered an infrequent finding, it is documented as a potential adverse effect.

Q: Can Adizem XL affect the use of hormonal contraceptives?

Diltiazem is known to affect the CYP3A4 enzyme, which is involved in processing certain other medicines, including hormonal contraceptives. Studies indicate that diltiazem may cause an increase in the blood concentration of certain hormones. This potential interaction is a topic for discussion with a healthcare provider.

Q: What kind of research evidence supports the use of Adizem XL for blood pressure control?

Official reviews of clinical trials confirm that diltiazem is an effective antihypertensive agent. Research has demonstrated that the drug significantly lowers both systolic and diastolic blood pressure compared to placebo across the dosage range studied, supporting its use for blood pressure control.

Q: Have studies examined how Adizem XL affects exercise tolerance?

Yes, studies involving diltiazem extended-release tablets have specifically examined its effects on exercise capacity. Regulatory documents state that the drug is indicated for use to improve exercise tolerance in individuals diagnosed with chronic stable angina.

Q: What is the process for switching from a different brand of diltiazem to Adizem XL?

If switching from a different formulation of diltiazem to Adizem XL, the dose is generally converted to the nearest equivalent total daily dose of the extended-release capsule. Regulatory guidance advises that once the appropriate dose is established, patients should avoid switching between different presentations of the drug.

Q: Why is Adizem XL sometimes prescribed with other types of blood pressure medication?

Adizem XL is officially indicated for the treatment of high blood pressure and can be used as a single-agent therapy. However, official labeling confirms that it may also be used in combination with other types of antihypertensive medicines, such as diuretics. This combined approach is sometimes used to achieve a more targeted and effective control of blood pressure.

Q: Does taking Adizem XL mean a person will no longer have angina attacks?

Adizem XL is prescribed to manage and treat chronic stable angina. Clinical trials indicate that the medicine is associated with a reduction in the frequency of angina episodes and can increase exercise tolerance. Regulatory documents, however, do not provide guarantees that taking the medicine will result in the complete cessation of all attacks.

Q: How does the extended-release formula of Adizem XL help maintain blood pressure over a full day?

The specialized extended-release formulation is designed to ensure the active ingredient is released in a controlled manner over a full 24-hour period. Official documents state that this mechanism leads to the maintenance of consistent therapeutic blood levels. This consistency is essential for providing steady cardiovascular control throughout the day.

Q: What is the difference between an extended-release capsule and an extended-release tablet of diltiazem?

Both the extended-release capsule and extended-release tablet forms of diltiazem are designed for a once-daily dosing schedule. Although they contain the same active ingredient, regulatory materials advise that these different forms may have distinct instructions for use and absorption characteristics. If switching between the two, a dose adjustment may be necessary.

How should Adizem XL be stored and disposed of?

Storage and Disposal of Adizem XL

Adizem XL (diltiazem hydrochloride) prolonged-release capsules must be stored under specific conditions to ensure product quality and integrity.

Storage Requirements

Temperature: Store the medicine at a temperature not above 25°C (77°F). Some regulatory documents specify Controlled Room Temperature, between 20° and 25°C (68° and 77°F), with permitted excursions.

Protection: The capsules must be protected from light and stored away from excessive humidity.

Container: The product must be kept in its original container, dispensed in a tight, light-resistant container, and stored out of the sight and reach of children.

Disposal

Any unused or expired Adizem XL must be discarded according to local regulations for medicinal waste. To protect the environment, the medicine should not be disposed of via household wastewater or trash unless officially authorized.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adizem XL found in:

A-Z Index: